Monopar Therapeutics (MNPR) director details 43,499-share distribution in Form 4

Rhea-AI Filing Summary

Monopar Therapeutics director reports indirect share distribution. A reporting person who serves as a director of Monopar Therapeutics disclosed an indirect disposition of 43,499 shares of common stock on 12/16/2025 at a stated price of $0 per share, coded as transaction type "J" (other). The filing explains this relates to a pro rata distribution of Monopar shares by Gem Pharmaceuticals, LLC to its members, in which the reporting person states they have no pecuniary interest.

After the transaction, the reporting person reports 567,580 Monopar shares held indirectly through Gem and 93,750 shares held by DMH Business LLC. As a manager of Gem and of DMH Business LLC’s controlling owner, the reporting person may be deemed to share voting and dispositive power over these shares but disclaims beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hendricks Diane

Role 10% Owner

Type	Security	Shares	Price	Value
Other	Common Stock	43,499	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 567,580 shares (Indirect, See footnote)

Footnotes (1)

1. Reported disposition relates to pro rata distribution by Gem Pharmaceuticals, LLC ("Gem") to its members in which the reporting person has no pecuniary interest. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and the reporting person, a manager of Gem, owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein. This is based upon the 93,750 shares of Monopar Common Stock that DMH Business LLC directly owns. As a manager of DMH Business LLC, Ms. Hendricks may be deemed to share voting and dispositive power over these 93,750 shares. Ms. Hendricks disclaims beneficial ownership of the 93,750 shares held by DMH Business LLC, except to the extent of her pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hendricks Diane

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE IL 60091

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		J(1)		43,499	D	$0	567,580	I	See footnote(1)
Common Stock								93,750	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reported disposition relates to pro rata distribution by Gem Pharmaceuticals, LLC ("Gem") to its members in which the reporting person has no pecuniary interest. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and the reporting person, a manager of Gem, owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein.

2. This is based upon the 93,750 shares of Monopar Common Stock that DMH Business LLC directly owns. As a manager of DMH Business LLC, Ms. Hendricks may be deemed to share voting and dispositive power over these 93,750 shares. Ms. Hendricks disclaims beneficial ownership of the 93,750 shares held by DMH Business LLC, except to the extent of her pecuniary interest therein.

	/s/ Quan Vu, Attorney-in-fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Monopar Therapeutics (MNPR) report?

The filing reports an indirect disposition of 43,499 shares of Monopar common stock on 12/16/2025, recorded with transaction code "J" (other) at a stated price of $0 per share.

Who is the reporting person in this Monopar Therapeutics (MNPR) Form 4?

The reporting person is identified as a director of Monopar Therapeutics, as indicated by the checked "Director" box in the relationship section.

Why were 43,499 MNPR shares distributed according to the filing?

The 43,499 shares disposition is described as a pro rata distribution by Gem Pharmaceuticals, LLC to its members, and the reporting person states they have no pecuniary interest in that distribution.

How many Monopar Therapeutics shares does the reporting person report after the transaction?

Following the reported transaction, the filing shows 567,580 shares of Monopar common stock held indirectly through Gem Pharmaceuticals, LLC and 93,750 shares held by DMH Business LLC.

What ownership does the reporting person disclaim in this MNPR Form 4?

The reporting person disclaims beneficial ownership of the Monopar shares owned by Gem Pharmaceuticals, LLC and the 93,750 shares held by DMH Business LLC, except to the extent of any pecuniary interest.

How is the reporting person connected to Gem Pharmaceuticals and DMH Business LLC?

The filing states that Pharma Investments LLC owns a controlling share of Gem Pharmaceuticals, LLC, and the reporting person owns a controlling share of Pharma and is a manager of Gem. The reporting person is also identified as a manager of DMH Business LLC, which directly owns 93,750 Monopar shares.